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Abstract 
Background 
Recent advances in therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) have 
ushered in a new era in chronic hepatitis treatment. Maximizing efficacy of these medicines will 
require engaging and retaining individuals in care. We carried out a systematic review of 
operational interventions to enhance chronic viral hepatitis (HBV, HCV) testing, linkage to care, 
treatment uptake, adherence, and viral suppression or cure. 
 
Methods 
We searched seven databases for randomized controlled trials (RCTs) or controlled non-
randomized studies (NRSs) examining operational interventions along the chronic viral hepatitis 
care continuum. Data from similar interventions were pooled and quality of evidence was 
assessed using the GRADE approach. 
 
Findings 
We included 56 studies that reported outcomes along the care continuum (41 for HCV and 18 
for HBV). All studies except one were from high-income countries. Lay health worker HBV test 
promotion interventions increased HBV testing rates (RR = 2.68 [1.82 – 3.93]). Clinician 
reminders to prompt HCV testing during clinical visits increased HCV testing rates (RR = 3.70 
[1.81 – 7.57]). Nurse-led educational interventions improved HCV treatment completion (RR = 
1.14 [1.05 – 1.23]) and cure (OR = 1.93 [1.44 – 2.59]). Coordinated mental health, substance 
use, and hepatitis treatment services increased HCV treatment uptake (OR = 3.03 [1.24 – 
7.37]), adherence (RR = 1.22 [1.05 – 1.41]), and cure (RR = 1.21 [1.07 – 1.38]) compared to 
usual care.  
 
Interpretation 
Several simple, inexpensive operational interventions can substantially improve engagement 
and retention along the chronic viral hepatitis care continuum. Further operational research to 
inform scale up of hepatitis services is needed in low- and middle-income countries.  
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Introduction 
Viral hepatitis is the seventh leading cause of mortality worldwide with an estimated 1.45 million 
deaths each year.1 Over 90% of these deaths are attributable to chronic infection with either 
hepatitis B virus (HBV) or hepatitis C virus (HCV).1 Effective antiviral treatment of chronic HBV 
and HCV infection can halt or even reverse progression of liver disease2,3 and reduce hepatitis 
related mortality.4 Current therapies for HBV and HCV are transforming clinical management of 
both diseases. The development of nucleos(t)ide analogues with low rates of resistance has 
provided improved treatment options for patients with HBV.5 The landscape of HCV has been 
altered by the introduction of short regimen all-oral direct acting agents.6 The full clinical impact 
of these therapies will be contingent on first engaging and then retaining individuals across a 
care continuum (Figure 1).  
 
Operational interventions are public health interventions to expedite movement across a 
continuum of care. Identifying which interventions can maximize engagement and retention 
along the chronic viral hepatitis care continuum is essential for several reasons. First, global 
data suggest most people with HBV7,8 or HCV9-11 do not know their serostatus, especially those 
from vulnerable groups and those living in low- and middle-income countries. Second, currently 
available population-level data indicate there is low test uptake and substantial loss throughout 
both the HBV and HCV care continuums.12,13 Third, the greatest burden of HBV and HCV is in 
low- and middle-income countries where health services are fragile and hepatology services are 
rudimentary.14-16 Simple and inexpensive operational interventions can maximize the impact of 
limited health services in these low-resource settings and some have shown efficacy in HIV 
research.17  
 
Although there are differences in the clinical management of HBV and HCV, we combined them 
for the purposes of this review because some interventions focus on both diseases and there 
are similar opportunities to improve service delivery. The WHO has proposed the goal of global 
elimination of viral hepatitis by 2030 with a 65% reduction in viral hepatitis related mortality.18 
These are ambitious targets. Operational interventions to optimize the delivery of hepatitis 
services are necessary in order to achieve this goal. The purpose of this review was to 
synthesize data on operational interventions for HBV and HCV testing, linkage to care, 
treatment uptake, adherence, and viral suppression or cure in adults. 
 
Methods 
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Search strategy and selection criteria 
This review was registered in PROSPERO (42014015094) and carried out according to 
PRISMA guidelines. Databases searched include PubMed/MEDLINE, EMBASE, WHO library, 
International Clinical Trials Registry, PsycInfo and CINAHL. Additionally, clinicaltrials.gov and 
conference archives for AIDS 2014 and IAS 2013 were searched to retrieve registered trials and 
accepted abstracts, respectively. The search was performed 09 March 2015 with a publication 
date limit of 31 December 2014. References of articles selected for inclusion were searched for 
additional citations. Search terms, with facets for HBV/HCV, interventions and adherence, are 
detailed in Supplementary Data 1. Only peer-reviewed randomized controlled trials (RCTs) or 
controlled non-randomized studies (NRSs) were included. We contacted authors directly 
regarding unclear study details. 
 
Our search strategy can be found in Supplementary Data 2. Briefly, we included studies 
investigating operational interventions at any point in the chronic viral hepatitis care continuum 
for people living with diagnosed or undiagnosed chronic viral hepatitis (HBV or HCV). Only non-
pharmaceutical intervention studies with primary or secondary outcomes of testing, linkage to 
care, treatment uptake, treatment adherence, treatment completion, treatment outcome, or 
disease endpoints were included. Study designs were required to have a comparator or control. 
In NRSs, control groups could be generated through historical comparisons before and after 
implementation of an intervention, convenience sampling, or other non-randomized design. 
Exclusion criteria included dissertations, non-English language publications, studies enrolling 
only pediatric populations, and publications failing to report the outcome data necessary for 
extraction. Operational interventions to prevent new infections, including vaccination programs, 
were excluded because they were not considered part of the chronic viral hepatitis care 
continuum. 
 
Data extraction and risk of bias assessment 
Titles, abstracts, and full texts were sequentially screened for inclusion by two independent 
reviewers. Disagreements were resolved by a third reviewer. Data were also extracted by two 
independent reviewers, with differences reconciled by a third reviewer. The following variables 
were extracted: authors, journal of publication, publication year, study design, population, 
inclusion and exclusion criteria, participant characteristics, sample size, study setting, 
intervention and control description, duration of intervention, results, and conclusions. To 
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maximize comparability between studies, data were extracted and analyzed according to 
intention-to-treat when possible, even if individual authors reported results or conclusions based 
on per-protocol analyses. Participants lost to follow-up were assumed to have not achieved the 
outcome under investigation in our intention-to-treat analyses. If a single study included two 
intervention arms that were grossly similar, data from both arms were pooled and compared 
against the control arm. 
 
Following data extraction, risk of bias was assessed for both RCTs and NRSs using the 
Cochrane Collaboration’s risk of bias tool.19 If a single study reported outcomes at multiple 
stages of the care cascade, risk of bias was assessed for each stage independently. Outcomes 
were evaluated along six domains: selection bias, performance bias, detection bias, attrition 
bias, reporting bias, and other bias. Reporting bias was assessed by comparing published 
outcomes to outcomes outlined in original study protocols, if original protocols were registered 
on Clinicaltrials.gov.  
 
Data analysis and quality assessment 
All included publications were assessed for comparability on the basis of intervention type, 
control condition, and outcome. Studies determined to be similar for intervention, control, and 
outcome were included in meta-analyses to determine pooled effect size. Pooled relative risks 
or odds ratios with confidence intervals and forest plots were generated using a random-effects 
model in Review Manager 5.3. The degree of heterogeneity between studies in a comparison 
was assessed by calculating I2. 
 
Meta-analyses that included both RCTs and NRSs were stratified by study design, and separate 
pooled effect sizes are available in Supplementary Data 3. Effect sizes reported in the results 
section only combined RCT and NRS results if the inclusion of NRSs did not meaningfully alter 
the estimate of an intervention’s effect.  
 
Whenever possible pooled results were reported as relative risk. When studies only reported 
odds ratios with confidence intervals, data were pooled using the generic inverse variance 
method, and a pooled odds ratio was reported. If a portion of the studies included in a 
comparison reported outcomes that had been adjusted using matching or statistical modeling 
(e.g. regression modeling), a sub-analysis was generated using only adjusted results. Funnel 
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plots were only used to screen for reporting bias if ten or more studies were included in a meta-
analysis. 
 
The quality of evidence was assessed according to the methodology described by the GRADE 
working group,20 and a GRADE table was generated for each meta-analysis and sub-analysis. 
Where specific interventions were directed at specific populations we did not downgrade for 
indirectness as these were populations of interest. For imprecision, the pooled sample size for 
each meta-analysis was compared against the optimal information size (OIS), which was 
calculated using an alpha of 0.05 and power of 80%. 
 
Results 
A total of 7,583 unduplicated citations were identified, and 56 studies were included (Figure 2). 
Figure 2 shows 56 studies included in our overall qualitative synthesis, but only 33 studies were 
included in our quantitative synthesis because their interventions and outcomes were directly 
comparable to at least one other included study, allowing for a total of 14 meta-analyses. A 
summary of findings from all 14 meta-analyses is presented in Table 1. Figure 3 shows forest 
plots for the three meta-analyses we thought were of greatest importance. Other forest plots are 
in Supplementary Data 3.   
The 56 studies included 47 published full-text manuscripts, five abstracts, and four clinical trials. 
Among all studies, 15 reported an outcome along the HBV care continuum, 38 reported an 
outcome along the HCV care continuum, and three studies reported outcomes involving both 
HCV and HBV. Details of all included studies for HBV testing, HCV testing, and HCV cure 
stages are reported in Tables 2, 3, and 4, respectively. Details of other stages are in 
Supplementary Data 4 and 5.  
 
All stages of the HCV care continuum were represented by included studies. The HBV care 
continuum was less well studied, with no studies reporting outcomes related to HBV treatment 
uptake, adherence, or viral suppression. Among studies investigating HCV treatment uptake, 
adherence, and cure, only two interventions provided participants with DAA-based treatment 
regimens at some point during the study period.21,22 The remaining studies exclusively provided 
interferon-based treatment regimens. 
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Fifty-five out of 56 studies were conducted in high-income countries, and one study was from a 
middle-income country (Turkey). Twenty-five studies (44.6%, 25/56) were RCTs, including eight 
cluster RCTs. The other 31 studies (55.4%, 31/56) were NRSs. Sample sizes ranged from 21 to 
36,987.  
 
All of the included studies were designed to investigate the impact of an intervention on 
progression through the viral hepatitis care continuum, and the results presented here are not a 
secondary analysis. One study included a cost-effectiveness evaluation of the intervention.23 
Risk of bias tables for included studies are presented in Supplementary Data 6. Fourteen meta-
analyses were performed where data were sufficiently comparable. GRADE results for all meta-
analyses are presented in Table 1. No funnel plots were generated because none of the 14 
meta-analyses included ten or more studies. 
 
HBV testing24-39 
Nine of the 16 studies of interventions to promote HBV testing were conducted in community 
settings. The remaining seven occurred in facilities where high-risk populations either lived or 
received healthcare (Table 2). All 16 interventional studies targeted populations at high-risk of 
HBV infection or HBV-related morbidity and mortality, mainly Asian migrants (Table 2). 
 
Self-reported HBV testing rates were higher among groups that received a single lay health 
worker educational intervention to improve HBV knowledge and promote testing compared to 
groups that received no or unrelated educational interventions (RR = 2.68, CI95 1.82 – 3.93, I2 
= 56%, n = 2757, moderate quality of evidence) (Figure 3). Six RCTs were included in this 
meta-analysis. In each intervention bicultural and bilingual community members were educated 
on HBV infection and trained to provide basic culturally-tailored HBV information and encourage 
referral for testing. These test promotion activities either occurred in individuals’ homes or at 
community-based organizations, such as churches, language study programs, or nail salons. All 
six studies targeted Asian migrant communities in the United States or Canada.  
 
Three before-after NRSs compared new institutional testing protocols for high-risk populations 
and supplemental provider education to previous standards of care. The meta-analysis showed 
improved HBV testing rates (RR = 3.77, CI95 2.04 – 6.97, n = 37,547, very low quality of 
evidence), though heterogeneity was high (I2 = 91%). 
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Two RCTs evaluated HBV education and pre-test counseling with on-site testing by healthcare 
professionals at health or social service sites utilized by high-risk groups. Meta-analysis found 
these interventions improved HBV testing rates (RR = 6.20, CI95 3.19 – 12.08, n = 2,789, low 
quality of evidence), however heterogeneity was moderately high (I2 = 69%). 
 
HBV linkage to care40,41 
Only two studies reported an outcome related to HBV linkage to care. One evaluated the impact 
of an informational letter on local HBV services, while the second compared a new electronic 
patient referral system to the prior standard of care (Supplementary Data 4). 
 
HCV testing28,34,35,42-51 
In contrast to interventions to improve HBV testing, which were primarily delivered in community 
settings, all 13 interventions to improve HCV testing either targeted healthcare providers or took 
place at an established healthcare or social service facility. The majority of studies limited their 
interventions to a specific high-risk population, most frequently current and former drug users 
and patients with mental health comorbidities (Table 3). 
 
Clinician reminders to prompt HCV testing during clinical visits increased HCV testing rates 
compared to no clinician reminders (RR = 3.70, CI95 1.81 – 7.57, n = 52,947, very low quality of 
evidence) (Figure 3). In one cluster RCT and two NRSs reminder stickers were placed in patient 
charts that either prompted providers to ask about HCV-associated risk behaviors or order 
testing for patients born within a high-prevalence birth cohort. Two studies used physical 
reminder stickers, while one study incorporated reminders into an electronic medical records 
system. Although all three studies involved patients seeing primary care providers in New York 
City clinics, heterogeneity was very high (I2 = 99%).  
 
HCV education and pre-test counseling with on-site testing by healthcare professions at 
facilities serving high-risk populations increased HCV testing compared to no education or 
counseling (RR = 2.77, CI95 1.11 – 6.93, n = 4,209, very low quality of evidence). Facilities 
were notably different among the studies, and included a shelter, methadone treatment site, 
hospital emergency department, outpatient mental health clinic, and inpatient psychiatric 
department. Heterogeneity was very high (I2 = 97%).  
 
HCV linkage to care28,34,43,52-56 
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There were eight studies reporting outcomes for interventions to link people with suspected or 
confirmed chronic HCV to care. Five of the eight interventions promoting linkage to care focused 
on people with current or past substance use (Supplementary Data 5).  
 
Interventions that provided facilitated referral increased patient attendance to HCV specialist 
visits compared to no facilitated referral (RR = 1.57, CI95 1.03 – 2.41, n = 437, moderate quality 
of evidence). In three RCTs specially trained staff at a site of established care guided patients 
with a positive HCV serology result through the referral process and helped them schedule 
specialist visits. There was high heterogeneity between reported effect sizes (I2 = 74%). 
 
Psychological counseling and motivational therapy for mental health and/or substance use 
issues as well as referral to longer term mental health services increased the number of referred 
patients eligible for treatment compared to usual care (OR = 3.42, CI95 1.81 – 6.49, n = 120, 
very low quality of evidence) and heterogeneity was very low (I2 = 0%). 
 
HCV treatment uptake43,52,54,57-61 
Eight studies reported HCV treatment uptake as an outcome. Interventions to improve HCV 
treatment uptake predominantly targeted patients with mental health and/or substance use 
comorbidities, with six of the eight studies at this stage exclusively studying this population 
(Supplementary Data 5). 
 
Coordinated mental health, substance use, and hepatitis treatment services did not significantly 
increase HCV treatment uptake (RR = 1.36, CI95 0.94 – 1.97, n = 846, very low quality 
evidence). Results from three studies, one RCT and two NRSs, were pooled for this meta-
analysis. In all three interventions a multi-disciplinary care team regularly met to discuss patient 
issues and coordinate treatment plans. All studies found rates of HCV treatment uptake to be 
higher in the intervention group compared to control, however heterogeneity was high (I2 = 
77%). 
 
HCV treatment adherence22,23,54,56,57,59,60,62-75 
With 21 studies reporting HCV treatment adherence (including treatment completion), this stage 
of the care continuum was best represented in the published literature. Unlike previous stages 
of the HCV care continuum, the majority of interventions reporting HCV treatment adherence 
outcomes did not target a particular high-risk group. Fifteen out of 21 studies included all adults 
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with chronic HCV infection who qualified for treatment. The other six studies only included 
adults living with HCV who also had mental health and/or substance use comorbidities 
(Supplementary Data 5). 
 
Coordinated mental health, substance use, and hepatitis treatment services improved treatment 
completion compared to usual care (RR = 1.22, CI95 1.05 – 1.41, n = 399, very low quality of 
evidence). Two RCTs and two NRSs were included in this meta-analysis. All four interventions 
involved regular contact between mental health and specialist treatment providers throughout 
the course of HCV treatment, and mental health services were arranged for those with 
comorbidities. Two studies also provided additional case management for the intervention 
group. All four studies reported increased treatment completion in the intervention group, and 
heterogeneity was very low (I2 = 0%). 
 
Two meta-analyses evaluated the impact of nurse-led educational sessions about HCV 
treatment on treatment adherence and treatment completion, respectively. This intervention did 
not significantly improve treatment adherence (RR = 1.08, CI95 0.87 – 1.34, n = 891, very low 
quality of evidence) though it did improve treatment completion (RR = 1.14, CI95 1.05 – 1.23, n 
= 965, very low quality of evidence). Three NRSs reported treatment adherence as an outcome, 
with moderate heterogeneity (I2 = 64%). Three NRSs and one RCT reported treatment 
completion as an outcome, with very low heterogeneity (I2 = 0%). The frequency and intensity of 
educational sessions varied widely across studies. 
 
HCV cure23,54,56-66,68,69,72,74-77 
Twenty studies reported SVR as an outcome. Most studies at this stage included all adults with 
chronic HCV who qualified for treatment, but eight studies exclusively targeted adults who had 
mental health and/or substance use comorbidities (Table 4). 
 
Coordinated mental health, substance use, and hepatitis treatment services improved SVR 
compared to usual care (RR = 1.21, CI95 1.07 – 1.38, n = 846, very low quality of evidence) 
(Figure 3). All five studies included in this meta-analysis, including two RCTs and three NRSs, 
reported increased SVR in the intervention group. Two of five studies also provided additional 
case management, while two others included enhanced therapeutic education for the 
intervention group. One study facilitated family member involvement in care decisions and 
community support. Heterogeneity in this meta-analysis was very low (I2 = 2%). 
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Nurse-led educational sessions about HCV treatment improved SVR compared to no education 
(OR = 1.93, CI95 1.44 – 2.59, n = 1460, low quality of evidence). Of the six studies examining 
this intervention, four were included in this meta-analysis because they reported results that 
employed statistical methods to adjust for confounding potentially introduced by non-
randomized study designs. All four studies reported increased SVR in groups that had received 
the educational intervention, and heterogeneity was very low (I2 = 0%).  
 
Directly observed therapy did not improve SVR compared to self-administered interferon 
therapy (OR = 1.49, CI95 0.72 – 3.08, n = 219, very low quality of evidence). Two of the three 
studies in this meta-analysis examined patients currently receiving methadone maintenance 
therapy, and heterogeneity between effect sizes was very low (I2 = 0%). 
 
Discussion 
Our review demonstrates that operational interventions can optimize the chronic viral hepatitis 
care continuum. Included studies were diverse with a range of interventions targeting both 
patients and providers. Existing systematic reviews have focused solely on HCV78-80 or 
restricted their study to one step of the care continuum78,80,81 or one type of intervention.82 
Furthermore, several reviews allowed inclusion of single arm studies79,81 or did not pool 
outcomes.79-82 Our review extends the literature by excluding non-comparator studies and 
carrying out meta-analyses on key HBV and HCV operational interventions and outcomes. We 
also improve the rigor of our analysis by using GRADE methodology to assess quality of 
evidence (Table 1). 
 
Our meta-analysis demonstrates task shifting educational programs to culturally appropriate lay 
health workers is effective in increasing HBV testing uptake. The six included studies were 
graded as moderate quality evidence. Although all lay health worker interventions were 
conducted among Asian immigrant populations in high-income countries, this particular type of 
intervention may apply to  other settings.83 Training provided for the lay health workers in the six 
studies was relatively simple and low cost. Qualitative research supports these types of 
interventions as feasible and acceptable to both those individuals tested and the lay health 
workers employed.84 Task shifting is a well-documented approach and recommended for 
strengthening service delivery capacity in a variety of clinical settings, particularly in the context 
of the efficient use of limited health resources in low- and middle-income countries.85-87  
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Our analysis found clinician reminders were effective in increasing HCV testing during clinical 
consultations. Included studies used electronic medical record prompts47 and physical 'risk 
testing' stickers placed on printed charts.44,49 This simple intervention could be easily 
implemented at low cost in both inpatient and outpatient settings. Clinician reminders are 
consistent with the broader shift towards improving health care quality through provider-initiated 
testing88 and systems-based approaches89 to improving clinical outcomes. Implementation is 
relatively easy and similar systems have demonstrated the effectiveness of clinician reminders 
in resource limited settings90. While increasing antibody testing is important, a crucial next step 
that was not evaluated in the majority of included studies is confirmatory RNA testing. Reflexive 
RNA testing is a similarly simple electronic task that has been validated53 but needs additional 
study. 
 
We found integration of mental health and substance use management with HCV treatment 
services was effective in promoting HCV treatment completion and cure (SVR). HCV 
disproportionately affects individuals with mental health and substance use disorders91. 
Traditionally, services for HCV treatment, mental health, and addiction management have been 
provided by separate clinicians located in different health facilities, which impedes 
communication and follow-up for the management of each respective condition92. While the 
multidisciplinary care interventions in this review were diverse, and at times complex, a likely 
key contributor to improved outcomes was co-location of services. Support for co-location as the 
primary driver of effect comes from literature from other communicable diseases in which co-
location of infectious disease and mental health services improved outcomes93,94. Furthermore, 
lack of transportation95, inadequate access to healthcare95, and delay in specialist input96 have 
all been identified as barriers to delivery of HCV treatment.  
 
Our review findings on operational interventions to promote testing can be generalized to a 
number of populations and settings. Among HCV studies, we found many interventions focused 
on serving PWID,21,28,31,34,43,46,50,52,55,60 including in settings such as general practice clinics,43 
substance use disorder clinics,28,46 emergency medical services,50 hepatitis clinics,31 methadone 
clinics,43,55 and prisons.46 Our data included one study among those actively using drugs50 and 
one study among those previously denied HCV treatment,52 suggesting a broad cross-section of 
PWID. Although similar structural issues challenge HCV service delivery in low and middle-
income countries, we identified no PWID HCV operational intervention research from these 
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settings. We speculate that some of the interventions identified in high-income countries, such 
as clinician reminders for HCV testing, could be adapted and used in low and middle-income 
country settings.  Among HBV studies, all interventions targeted populations at high-risk of HBV 
infection or HBV-related complications, including nine studies of Asian migrants. The 
generalizability of these high-income studies to low and middle-income settings should be done 
with caution.  
 
Our review has several policy implications. First, we grouped the HBV and HCV care 
continuums together. While laboratory testing, antiviral therapy, and outcomes differ between 
these two viruses, the basic steps from testing to treatment are similar. Oral direct acting 
antivirals (DAAs) for treatment of HCV are ostensibly analogous to HBV antivirals, although 
treatment is of finite duration. While affected populations may vary between countries and 
contexts, similar programmatic structures may suit the management of both infections, including 
the operational interventions described here. Second, a number of the interventions analyzed in 
this review were of low cost and could be implemented in resource-limited settings. Finally, the 
interventions described are essentially systems based, dependent on the organization of 
programs rather than the quality of hospital care or types of medicines available. The 
technology to implement these interventions is already available in many settings. In addition, 
many of these interventions can be implemented at the local level and are not dependent on 
higher-level governmental authorization. 
 
There are several limitations to our review. First, outcomes that were studied were intermediate 
outcomes related to diagnosis and treatment, not disease endpoints such as morbidity and 
mortality associated with HBV and HCV. However, it is well known that treatment reduces liver-
related complications and hepatocellular carcinoma incidence4,97. Second, almost all studies in 
HCV were carried out with interferon-based therapies. Compared with pegylated interferon, 
current DAA-based regimens are simpler to administer, more effective, and better tolerated6. 
With these agents, treatment uptake and outcomes will likely improve 98. The emphasis now 
shifts to testing and linkage to care interventions as treatment eligibility expands. The 
psychosocial issues that impact compliance in vulnerable HCV populations however remain the 
same. With development of resistance a major concern with DAAs, interventions that promote 
adherence remain relevant. Third, nearly all studies were implemented in high-income 
countries. Further research is needed in low and middle-income countries. Fourth, several 
meta-analyses only had a few contributing studies. As a result, there were insufficient data to 
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undertake subanalyses based on HIV-hepatitis co-infection, subpopulation, and other variables 
that may contribute to effectiveness. Fifth, we excluded non-English literature. This was due to a 
concern about lower quality of evidence in non-English journals, empirical evidence that 
restricting non-English language research does not lead to selection bias, and logistical issues. 
 
Finally, there was a relative dearth of quality studies in our review.  More than half the studies 
used a non-randomized design, and the majority did not adjust for potential confounders. 
Combining NRSs with RCTs increases the potential for selection bias and may contribute to 
high degree of heterogeneity observed in several meta-analyses. As several stages and 
intervention types were primarily investigated through NRSs, the inclusion of NRSs was 
necessary to accurately represent the full spectrum of operational interventions evaluated in the 
literature. Stratification of meta-analyses by study design did not find large differences between 
estimated effect sizes. Heterogeneity in pooled effect sizes was more likely due to differences in 
frequency and duration of intervention exposure, implementation, and populations under study, 
rather than study design. Most meta-analyses included a small number of studies (less than 
four), which also contributes to high heterogeneity and limits confidence in the effect size 
estimates. Assessments of some interventions were also disproportionately affected by results 
of a single study. It should also be noted that a number of innovative interventions such as 
point-of-care testing and electronic patient referral systems appeared promising and require 
further research. 
 
We identified several priorities for future research. The lack of data from low- and middle-
income settings was disappointing, given the vast bulk of people living with HBV and HCV 
across the world reside in these settings14,15. Most of our review findings were graded low or 
very low. High quality evidence provides a strong basis for forming guideline recommendations 
for program managers, clinicians, and others working in the field.  RCTs in operational research 
can be costly, difficult to carry out, and potentially unethical in resource constrained settings. 
Methods to ameliorate these issues include pragmatic trials that mirror real world conditions to 
maximize generalizability and effectiveness-implementation hybrid trials that simultaneously 
evaluate impact and strategy of intervention delivery.99 These types of implementation science 
trials could help move forward hepatitis service provision while definitive RCT trials are 
underway. Formal cost-effectiveness research may be useful to convince policy makers about 
the importance of developing HBV and HCV operational interventions. Further research is also 
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needed in a number of key steps across the care continuum, in particular HBV treatment 
uptake, adherence, and viral suppression.  
 
Our systematic review demonstrates a range of relatively simple, inexpensive operational 
interventions can substantially improve engagement and retention along the chronic viral 
hepatitis care continuum. We identified the importance of integrated approaches to hepatitis 
care and treatment for specific vulnerable populations. High uptake along the continuum will 
become increasingly important as access to effective HBV and all-oral HCV medicines expands. 
The interventions identified in this review may be useful to augment hepatitis programs 
worldwide. As global momentum grows for addressing hepatitis at the population level, further 
operational research is necessary to optimize chronic hepatitis services. 
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Research in context 
Evidence before this study 
Chronic hepatitis B and C are major public health threats; however current therapies for HBV 
and HCV are transforming clinical management of both diseases. Optimal care and treatment 
are dependent on effective program implementation. Operational interventions may expedite 
movement across the continuum (cascade) of care. Existing systematic reviews have focused 
solely on HCV, restricted investigation to one step of the care continuum, a single type of 
intervention or did not pool outcomes from individual studies. Our search focused on studies 
investigating operational interventions at any point in the chronic viral hepatitis care continuum 
for people living with diagnosed or undiagnosed chronic viral hepatitis. We searched Pubmed, 
EMBASE, WHO library, International Clinical Trials Registry Platform, Psychinfo, and Cinahl for 
full-text or abstract entries, accepted scientific conference abstracts, clinical trials registered on 
Clinicaltrials.gov and references of included articles. The combination of search terms included 
“Hepatitis B”, ”Hepatitis C”, “chronic viral hepatitis”, “Intervention” and various types of 
operational interventions including behavior and structural as well as terms focused on steps in 
the continuum including “Screen”, “ test”, “ Linkage”, “Referral” as well as adherence, SVR or 
viral suppression. We included literature published up to 31 December 2014. 
 
Added value of this study 
Our review extends the literature by excluding non-comparator studies and carrying out meta-
analyses on key HBV and HCV operational interventions and outcomes. We also improve the 
rigor of our analysis by using GRADE methodology to assess quality of evidence. Our 
systematic review demonstrated a range of relatively simple, inexpensive operational 
interventions can substantially improve engagement and retention along the chronic viral 
hepatitis care continuum, thereby optimizing the implementation of screening, care and 
treatment programmes. 
 
Implications of all the available evidence 
Operational interventions should be included in chronic viral hepatitis screening, diagnosis and 
treatment programmes to optimize hepatitis care outcomes. Our findings suggest that a range of 
operational interventions have been developed which could enhance HBV and HCV service 
delivery. 
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Figures and Tables 
 
Figure 1: Overview of the chronic viral hepatitis care continuum, including testing, linkage to care, treatment uptake, treatment 
adherence, and viral suppression or cure. 
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Figure 2: Summary of the Article Search, Screening, and Selection Process. 
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Figure 3: Meta-analysis of the impact of lay health worker educational interventions on HBV testing uptake, clinician reminders to test 
during clinical visits on HCV testing, and coordinated mental health, substance use, and hepatitis treatment services on SVR. 
Forest plots for all 14 meta-analysis included in this review can be found in Supplemental Data 3.
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